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Article Information  ABSTRACT 
Received: 21st May 2017  Parkinson’s disease is one of the most common neurodegenerative diseases. The motor system 
is eventually damaged which affects the voluntary movements in a patient. It leads to the death 
of vital nerve cells in the brain. Women have lesser prevalence due to the hormone called 
Estrogen which has been playing a significant role in human body. Most of the treatments focus 
on the balance of Dopamine in the brain which is done with the help of levodopa but the side 
effects seen in the patients were mild nausea, loss of appetite, heart burn, diarrhea, and many 
more.  The cause of the disease is still unknown but its occurrence is mainly because of genetic 
and environmental factors. This review focuses on the combination therapy of levodopa and 
Carbidopa to treat the symptoms of Parkinson’s disease. 
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INTRODUCTION 
Parkinson’s mainly affects the old population. It is a voluntary 
movement motor neuron disorder which leads to tremor, 
rigidity, hypokinesia and later leads in the development of 
secondary manifestations for example dementia, defective 
posture, and trouble while speaking.  
 
The neurons in the substantia nigra are destroyed which leads 
to the decrease in dopamine levels in the brain which controls 
all the voluntary movements and muscle tone of the body. 
Levodopa is a dopamine precursor while Carbidopa is a 
peripheral decarboxylase inhibitor. Both levodopa and 
Carbidopa are used in combination for better results in treating 
the symptoms of Parkinson’s disease [1].  
 
The enzyme L-aromatic amino acid decarboxylase converts 
levodopa into dopamine. Being a peripheral decarboxylase 
inhibitor, Carbidopa, does not allow dopamine formation from 
levodopa in the bloodstream. Due to this, more amount of 
dopamine can be made available in the brain [2].  
 
PATHOLOGY & ETIOLOGY OF PARKINSON’S DISEASE 
The symptoms of Parkinson’s disease start with the death of 
dopaminergic neurons which almost destroys half of the brain. 
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The primary symptoms affect the medulla oblongata and the 
olfactory bulb, followed by secondary symptoms which 
directly affect the substantia nigra and the areas of the forebrain 
[3].  
 
According to the researchers, the start of the symptoms 
sometimes can be non motor instead of motor for example 
sleeping disorders, depression and mental changes. The reason 
can be genetic disorders like mutations or environmental 
factors like cigarette smoking and exposure to pesticides [4]. 
 
MECHANISM OF ACTION OF LEVODOPA & 
CARBIDOPA 
Levodopa is very effective and one of the widely used drug for 
the treatment of Parkinson’s disease [5]. Levodopa is used in 
combination with Carbidopa, since levodopa cannot cross the 
blood brain barrier but Carbidopa can easily cross the blood 
brain barrier without affecting the levels of plasma 
concentrations. Carbidopa also helps in increasing the 
bioavailability of levodopa [6].  
 
Aromatic-L-amino acid decarboxylase helps in catabolizing 
levodopa in the blood. The dopamine which is obtained from 
levodopa is stored in the dopamine receptors and then is 
utilized when required [7]. With the combination of levodopa 
and Carbidopa, more concentration is available in the brain. 
Aromatic-L-amino acid decarboxylase is found in many cells in 
the body but not in the dopaminergic neurons, because of the 
low affinity [8].  
 
ON GOING STUDIES 
Levodopa-Carbidopa intestinal gels (LCIG) have been 
developed to treat the patients. But the complications seen in 
the patients were vitamins deficiency, abdominal pain, 
procedural pain and many more. However, it showed more 
effect as compared to the orally administered levodopa. The 
intestinal gel is effective apart from the machines and 
equipments complications. The bioavailability was seen to be 
doubled and unaffected [9]. 
 
The LCIG is available in Europe for the patients experiencing 
severe motor dysfunctions. Used mainly in the patients with 
advanced dyskinesia. The dose the gel is titrated according to 
the patient’s condition and is given three times a day, which 
include a morning dose, the next dose is given approximately at 
night and the last dose is an extra dose which can be used in 
emergencies. LCIG can be given as a single dose or with the 
combination of levodopa and Carbidopa oral administration for 
slow release and improved sleep for the patient at night [10]. 
 
CONCLUSION 
There are various categories of therapies and combination 
therapies available to treat the symptoms of Parkinson’s 
disease. But the widely used therapy is the combination therapy 
of levodopa and Carbidopa because of the artificially 
synthesized dopamine from levodopa. Though there are no 
medications available to treat the disease. 
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